Back to News
Market Impact: 0.2
Vistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up
Source: Nasdaq
Healthcare & Biotech
Vistagen Therapeutics announced preliminary data from the open-label extension of its PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder. The article provides no efficacy, safety, or financial details, limiting assessment of the clinical readout's significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
VTGN0.45
More News
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas
- In Senegal, a mother’s ordeal exposes a health system under strain
- Halozyme Therapeutics completes $1.5 billion convertible notes offering
- Trump administration removes around 760,000 Obamacare enrollments, alleging fraud
- Dozens of people sue GLP-1 drug companies over alleged vision loss